Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2023 | Nov. 10, 2023 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001368148 | |
Entity Registrant Name | ATHERSYS, INC / NEW | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-33876 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-4864095 | |
Entity Address, Address Line One | 3201 Carnegie Avenue | |
Entity Address, City or Town | Cleveland | |
Entity Address, State or Province | OH | |
Entity Address, Postal Zip Code | 44115-2634 | |
City Area Code | 216 | |
Local Phone Number | 431-9900 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 61,718,815 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 1,020 | $ 9,038 |
Prepaid clinical trial costs | 0 | 2,747 |
Prepaid expenses and other | 1,210 | 1,034 |
Total current assets | 2,230 | 13,535 |
Operating right-of-use assets, net | 26 | 7,846 |
Property and equipment, net | 4,236 | 4,214 |
Other Assets | 936 | 2,136 |
Total assets | 7,428 | 27,731 |
Current liabilities: | ||
Accounts payable | 9,295 | 27,765 |
Deferred accounts payable to Supplier | 7,862 | 0 |
Operating lease liabilities, current | 7,792 | 746 |
Accrued compensation and related benefits | 890 | 1,090 |
Accrued clinical trial related costs | 360 | 7,231 |
Accrued expenses and other | 1,490 | 1,078 |
Note Payable | 10,785 | 0 |
Deferred revenue - Healios | 150 | 0 |
Warrant liability | 0 | 534 |
Total current liabilities | 38,624 | 38,444 |
Operating lease liabilities, non-current | 0 | 7,939 |
Stockholders’ equity: | ||
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at September 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 600,000,000 shares authorized with 26,758,431 and 17,986,147 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 27 | 18 |
Additional paid-in capital | 642,754 | 632,009 |
Accumulated deficit | (680,384) | (655,878) |
Accumulated other comprehensive income | 1,208 | 0 |
Total stockholders’ deficit | (36,395) | (23,851) |
Total liabilities and stockholders’ equity | 7,428 | 27,731 |
Affiliated Entity [Member] | ||
Current assets: | ||
Accounts receivable from Healios | 0 | 716 |
Current liabilities: | ||
Advance from Healios | $ 5,199 | $ 5,199 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2023 | Dec. 31, 2022 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 26,758,431 | 17,986,147 |
Common stock, shares outstanding (in shares) | 26,758,431 | 17,986,147 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | ||
Revenues | |||||
Contract revenue from Healios | $ 0 | $ 65 | $ 49 | $ 5,294 | |
Total revenues | 0 | 65 | 49 | 5,294 | |
Costs and expenses | |||||
Research and development | 3,995 | 12,424 | 19,111 | 54,162 | |
General and administrative | 2,808 | 3,737 | 7,968 | 12,999 | |
Depreciation | 977 | 617 | 1,072 | 1,482 | |
Total costs and expenses | 7,780 | 16,778 | 28,151 | 68,643 | |
Loss from operations | (7,780) | (16,713) | (28,102) | (63,349) | |
Other income, net1 | [1] | 4,009 | 3,044 | 3,596 | 3,816 |
Net loss | $ (3,771) | $ (13,669) | $ (24,506) | $ (59,533) | |
Net loss per share, basic and diluted (in dollars per share) | $ (0.15) | $ (1.15) | $ (1.16) | $ (5.58) | |
Weighted average shares outstanding, basic and diluted (in shares) | 24,492 | 11,855 | 21,184 | 10,676 | |
Other comprehensive income | |||||
Net loss | $ (3,771) | $ (13,669) | $ (24,506) | $ (59,533) | |
Fair value change due to company credit risk | 1,208 | 0 | 1,208 | 0 | |
Total Other comprehensive income | 1,208 | 0 | 1,208 | 0 | |
Net loss and comprehensive loss | $ (2,563) | $ (13,669) | $ (23,298) | $ (59,533) | |
[1]See Footnote 10 for components of other income, net |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2021 | 0 | 9,713,767 | ||||
Balance at Dec. 31, 2021 | $ 0 | $ 10 | $ 599,703 | $ 0 | $ (583,344) | $ 16,369 |
Stock-based compensation | $ 0 | $ 0 | 1,410 | 0 | 0 | 1,410 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 148,611 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 0 | (58) | 0 | 0 | (58) |
Net loss | $ 0 | $ 0 | 0 | 0 | (22,216) | (22,216) |
Issuance of common stock (in shares) | 0 | 129,333 | ||||
Issuance of common stock | $ 0 | $ 0 | 4,803 | 0 | 0 | 4,803 |
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 129,333 | ||||
Balance (in shares) at Mar. 31, 2022 | 0 | 9,991,711 | ||||
Balance at Mar. 31, 2022 | $ 0 | $ 10 | 605,858 | 0 | (605,560) | 308 |
Balance (in shares) at Dec. 31, 2021 | 0 | 9,713,767 | ||||
Balance at Dec. 31, 2021 | $ 0 | $ 10 | 599,703 | 0 | (583,344) | 16,369 |
Net loss | (59,533) | |||||
Other comprehensive income | 0 | |||||
Balance (in shares) at Sep. 30, 2022 | 0 | 12,933,736 | ||||
Balance at Sep. 30, 2022 | $ 0 | $ 13 | 626,252 | 0 | (642,877) | (16,612) |
Balance (in shares) at Mar. 31, 2022 | 0 | 9,991,711 | ||||
Balance at Mar. 31, 2022 | $ 0 | $ 10 | 605,858 | 0 | (605,560) | 308 |
Stock-based compensation | $ 0 | $ 0 | 1,945 | 0 | 0 | 1,945 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 227,955 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 0 | (40) | 0 | 0 | (40) |
Net loss | $ 0 | $ 0 | 0 | 0 | (23,648) | (23,648) |
Issuance of common stock (in shares) | 0 | 784,724 | ||||
Issuance of common stock | $ 0 | $ 1 | 9,697 | 0 | 0 | 9,698 |
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 784,724 | ||||
Balance (in shares) at Jun. 30, 2022 | 0 | 11,004,390 | ||||
Balance at Jun. 30, 2022 | $ 0 | $ 11 | 617,460 | 0 | (629,208) | (11,737) |
Stock-based compensation | $ 0 | $ 0 | 2,001 | 0 | 0 | 2,001 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 9,346 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 0 | (33) | 0 | 0 | (33) |
Net loss | $ 0 | $ 0 | 0 | 0 | (13,669) | (13,669) |
Issuance of common stock (in shares) | 0 | 1,200,000 | ||||
Issuance of common stock | $ 0 | $ 1 | 4,592 | 0 | 0 | 4,593 |
Other comprehensive income | 0 | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 1,200,000 | ||||
Pre-funded warrant exercise (in shares) | 0 | 720,000 | ||||
Pre-funded warrant exercise | $ 0 | $ 1 | 2,232 | 0 | 0 | 2,233 |
Balance (in shares) at Sep. 30, 2022 | 0 | 12,933,736 | ||||
Balance at Sep. 30, 2022 | $ 0 | $ 13 | 626,252 | 0 | (642,877) | (16,612) |
Balance (in shares) at Dec. 31, 2022 | 0 | 17,986,147 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 18 | 632,009 | 0 | (655,878) | (23,851) |
Stock-based compensation | $ 0 | $ 0 | 707 | 0 | 0 | 707 |
Stock Issue- warrant exercise (in shares) | 0 | 344,170 | ||||
Stock Issue- warrant exercise | $ 0 | $ 0 | 0 | 0 | 0 | 0 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 118,172 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 0 | (56) | 0 | 0 | (56) |
Net loss | $ 0 | $ 0 | 0 | 0 | (7,811) | (7,811) |
Balance (in shares) at Mar. 31, 2023 | 0 | 18,448,489 | ||||
Balance at Mar. 31, 2023 | $ 0 | $ 18 | 632,660 | 0 | (663,689) | (31,011) |
Balance (in shares) at Dec. 31, 2022 | 0 | 17,986,147 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 18 | 632,009 | 0 | (655,878) | (23,851) |
Net loss | (24,506) | |||||
Other comprehensive income | 1,208 | |||||
Balance (in shares) at Sep. 30, 2023 | 0 | 26,758,431 | ||||
Balance at Sep. 30, 2023 | $ 0 | $ 27 | 642,754 | 1,208 | (680,384) | (36,395) |
Balance (in shares) at Mar. 31, 2023 | 0 | 18,448,489 | ||||
Balance at Mar. 31, 2023 | $ 0 | $ 18 | 632,660 | 0 | (663,689) | (31,011) |
Stock-based compensation | $ 0 | $ 0 | 568 | 0 | 0 | 568 |
Stock Issue- warrant exercise (in shares) | 0 | 813,000 | ||||
Stock Issue- warrant exercise | $ 0 | $ 1 | (1) | 0 | 0 | 0 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 257,358 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 0 | (75) | 0 | 0 | (75) |
Net loss | $ 0 | $ 0 | 0 | 0 | (12,924) | (12,924) |
Issuance of common stock (in shares) | 0 | 2,315,000 | ||||
Issuance of common stock | $ 0 | $ 2 | 3,336 | 0 | 0 | 3,338 |
Warrant Liability | $ 0 | $ 0 | 2,685 | 0 | 0 | 2,685 |
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 2,315,000 | ||||
Balance (in shares) at Jun. 30, 2023 | 0 | 21,833,847 | ||||
Balance at Jun. 30, 2023 | $ 0 | $ 21 | 639,173 | 0 | (676,613) | (37,419) |
Stock-based compensation | $ 0 | $ 0 | 646 | 0 | 0 | 646 |
Stock Issue- warrant exercise (in shares) | 0 | 557,000 | ||||
Stock Issue- warrant exercise | $ 0 | $ 1 | (1) | 0 | 0 | 0 |
Issuance of common stock under equity compensation plan (in shares) | 0 | 155,084 | ||||
Issuance of common stock under equity compensation plan | $ 0 | $ 1 | (51) | 0 | 0 | (50) |
Net loss | $ 0 | $ 0 | 0 | 0 | (3,771) | (3,771) |
Issuance of common stock (in shares) | 0 | 4,212,500 | ||||
Issuance of common stock | $ 0 | $ 4 | 2,987 | 0 | 0 | 2,991 |
Other comprehensive income | $ 0 | $ 0 | 0 | 1,208 | 0 | 1,208 |
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 4,212,500 | ||||
Balance (in shares) at Sep. 30, 2023 | 0 | 26,758,431 | ||||
Balance at Sep. 30, 2023 | $ 0 | $ 27 | $ 642,754 | $ 1,208 | $ (680,384) | $ (36,395) |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Operating activities | |||
Net loss | $ (13,669) | $ (24,506) | $ (59,533) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation | 617 | 1,072 | 1,482 |
Gain on debt extinguishment | 0 | (2,611) | 0 |
Loss from impairment of assets | 7,746 | 5,435 | |
Allowance for doubtful accounts | 664 | 0 | |
Stock-based compensation | 1,921 | 5,356 | |
Change in Paid-in-Kind (PIK) Interest Accrual | 568 | 0 | |
Change in fair value of Note Payables | 0 | (3,192) | 0 |
Gain on sale of assets | 0 | (11) | |
Loss on abandonment of fixed assets | 427 | 0 | |
Change in fair value of warrant liabilities | (2,784) | 2,151 | (2,784) |
Issuance costs allocated to warrant liabilities | 500 | 0 | 560 |
Changes in operating assets and liabilities: | |||
Accounts receivable from Healios - billed and unbilled | 52 | 3,754 | |
Prepaid expenses, deposits and other | (163) | (1,262) | |
Accounts payable, accrued expenses and other | 1,323 | 4,472 | |
Accounts payable to Healios | 0 | (1,119) | |
Deferred revenue - Healios | 150 | (3,340) | |
Net cash used in operating activities | (14,398) | (46,990) | |
Investing activities | |||
Proceeds from the sale of equipment | 227 | 41 | |
Purchases of equipment | 0 | (2,044) | |
Net cash provided (used) in investing activities | 227 | (2,003) | |
Financing activities | |||
Proceeds from issuance of common stock, net of issuance cost | 0 | 14,500 | |
Proceeds from the issuance of common stock and warrants, net of issuance cost | 6,334 | 10,997 | |
Proceeds from the exercise of pre-funded warrants | 1 | 2 | |
Shares retained for withholding tax payments on stock-based awards | (182) | (131) | |
Net cash provided by financing activities | 6,153 | 25,368 | |
Decrease in cash and cash equivalents | (8,018) | (23,625) | |
Cash and cash equivalents at beginning of the period | 9,038 | 37,407 | |
Cash and cash equivalents at end of the period | $ 13,782 | 1,020 | 13,782 |
Noncash financing activities | |||
Issuance of warrants | 413 | ||
Reclass of warrant liability to additional paid-in capital upon exercise | $ 2,685 | $ 2,231 |
Note 1 - Background and Basis o
Note 1 - Background and Basis of Presentation | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Organization Athersys, Inc., including its consolidated subsidiaries (collectively, “we,” “us,” “our,” “Athersys,” and the “Company”), is a biotechnology company focused in the field of regenerative medicine and operates in one business segment. Our operations consist of research, clinical development activities, manufacturing and manufacturing process development activities, and our most advanced program is in a pivotal Phase 3 Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10 December 31, 2022 April 3, 2023. X. not not The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10 2. Reverse Stock Split On August 26, 2022, 1 not third |
Note 2 - Going Concern
Note 2 - Going Concern | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | 2. We have prepared our unaudited condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception in 1995 one At September 30, 2023 no may not not may |
Note 3 - Accounting Standards A
Note 3 - Accounting Standards Adopted | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Accounting Standards Update and Change in Accounting Principle [Text Block] | 3. In June 2016, 2016 13, Measurement of Credit Losses on Financial Instruments (Topic 326 2016 13, 2019 10, Financial Instruments - Credit Losses (Topic 326 January 2023. not |
Note 4 - Net Loss Per Share
Note 4 - Net Loss Per Share | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic and diluted net loss per share have been computed using the weighted-average number of shares of our common stock outstanding during the period. As of September 30, 2023 not September 30, 2023 August 2021 not September 30, 2023 August 2022, September 2022, November 2022, April 2023, August 2023, The following instruments were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 Stock options 1,119,369 1,280,173 1,119,369 1,280,173 Restricted stock units 301,029 103,065 301,029 103,065 Convertible Note - refer to Note 11 11,538,461 — 11,538,461 — Warrants - refer to Note 8 45,714,090 3,920,000 45,714,090 4,320,000 Total 58,672,949 5,303,238 58,672,949 5,703,238 |
Note 5 - Property and Equipment
Note 5 - Property and Equipment, Net | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5 Property and Equipment, net For the periods ended September 30, December 31, Property and equipment consists of (in thousands): 2023 2022 Laboratory equipment $ 8,352 $ 7,576 Office equipment and leasehold improvements 3,398 3,934 Equipment not yet in service 2,850 2,313 14,600 13,823 Accumulated depreciation and amortization (10,364 ) (9,609 ) $ 4,236 $ 4,214 Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not June 2022, 2022, We have disposed of gross assets of approximately $1.0 million with accumulated depreciation of $0.4 million, for $0.3 million in cash, which resulted in a loss of $0.3 million for the nine September 30, 2023 September 30, 2022 no three September 30, 2023 nine September 30, 2022 On June 9, 2023, nine September 30, 2023 |
Note 6 - Collaborative Arrangem
Note 6 - Collaborative Arrangements and Revenue Recognition | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 6. Healios Collaboration We have a licensing agreement with Healios to primarily develop and commercialize our cell therapy technologies for certain disease indications in Japan, pursuant to which we received nonrefundable license fee payments and are entitled to royalties on net sales. We also have the right to receive development and commercial milestone payments from Healios, subject to certain potential credits that have been negotiated from time-to-time and are associated with modifications to the arrangement. Healios is responsible for the development and commercialization of the licensed products in the licensed territory, and we provide certain services to Healios for which we are paid. In August 2021, September 30, 2023 In addition, under the Framework Agreement, the Company was entitled to a $3.0 million milestone payment from Healios and was obligated to pay Healios $1.1 million by December 31, 2022. September 2022, September 2022, 2023 In August 2021, “2021 2021 606, Revenue from Contracts with Customers 718, Compensation Stock Compensation September 30, 2023 2021 not not not 8, In August 2023, 2 Healios has alleged that we are in material breach of our Framework Agreement for, among other things, not no Healios Revenue Recognition At the inception of the Healios arrangement and again each time that the arrangement has been modified, all material performance obligations were identified, which include (i) licenses to our technology, (ii) product supply services, and (iii) manufacturing services provided on Healios’ behalf. Under the Framework Agreement, it was determined there was one performance obligation for services necessary for regulatory approvals, manufacturing readiness, and commercial launch in Japan. We determined the transaction price included estimated payments for reimbursable services to be performed by us for Healios and the $3.0 million milestone payment. We allocated the total transaction price to this one performance obligation. We began recognizing revenue in the third 2021 September 30, 2023 three September 30, 2023 three September 30, 2022 three September 30, 2023 September 30, 2022 Accounts receivable from Healios Accounts receivable from Healios are related to our contracts and are recorded when the right to consideration is unconditional at the amount that management expects to collect. Accounts receivable from Healios do not thirty forty-five September 30, 2023 Deferred Revenue - Healios The amounts included in deferred revenue - Healios are considered a contract liability connected to the funds received as part of the MOU. During the nine September 30, 2023 nine September 30, 2022 Advance from Healios In 2017, may Disaggregation of Revenues We recognize product supply revenue at a point in time upon delivery, as defined in the applicable product supply contracts, while service revenue is recognized when earned over time. The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands): Three months ended Three months ended September 30, 2023 September 30, 2022 Point in Point in Time Over Time Time Over Time Contract Revenue from Healios Product supply revenue $ — $ — $ — $ — Service revenue — — — 65 Total disaggregated revenues $ — $ — $ — $ 65 Nine months ended Nine months ended September 30, 2023 September 30, 2022 Point in Point in Time Over Time Time Over Time Contract Revenue from Healios Product supply revenue $ 49 $ — $ — $ — Service revenue — — — 5,294 Total disaggregated revenues $ 49 $ — $ — $ 5,294 |
Note 7 - Stock-based Compensati
Note 7 - Stock-based Compensation | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 7. Our 2019 September 30, 2023 On September 27, 2022, 2019 As of September 30, 2023 September 30, 2023 three September 30, 2023 2022 September 30, 2023 2026 |
Note 8 - Stockholders' Equity a
Note 8 - Stockholders' Equity and Warrants | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | 8. Equity and Warrants At September 30, 2023 September 30, 2022 September 30, 2023 2022 August 2022 On August 15, 2022, On August 15, 2022, “August 2022 “August 2022 “August 2022 August 2022 August 2022 August 2022 August 2022 August 2022 August 2022 six five August 2022 August 2022 August 2022 August 17, 2022 August 29, 2022, August 2022 August 2022 Pursuant to the August 2022 twelve On September 22, 2022, August 2022 “August 2022 August 2022 seven six On September 22, 2022, August 2022 “September 2022 seven six The Company has assessed the August 2022 August 2022 September 2022 10 December 31, 2022. 815, not three September 30, 2022. On April 17, 2023, August 2022 September 2022 August 2022 September August 2022 September 2022 815, April 17, 2023, On August 17, 2023, August September August September During the three nine September 30, 2023 three nine September 30, 2022 November 2022 On November 9, 2022, On November 9, 2022, “November 2022 “November 2022 “November 2022 November 2022 November 2022 November 2022 November 2022 November 2022 November 2022 November 2022 November 2022 November 2022 five November 10, 2022, November 2022 The November 2022 815, November 2022 April 2023 On April 18, 2023, On April 18, 2023, “April 2023 “April 2023 “April 2023 April 2023 April 2023 April 2023 April 2023 six April 2023 not April 2023 seven six April 19, 2023, The April 2023 815, April 2023 August 2023 On August 17, 2023, On August 17, 2023, “August 2023 “August 2023 “August 2023 one one August 2023 one August 2023 August 2023 August 2023 one not one five one one August 21, 2023, The August 2023 August 2023 815, August On October 11, 2023, August 17, 2022, September 22, 2022, November 10, 2022, August 21, 2023. On October 30, 2023, October 16, 2023 1 $0.1395 2 3 Healios 2021 In August 2021, 2021 2021 2021 2021 may Equity Purchase Agreement We previously had equity purchase agreements in place since 2011 May 12, 2022, “2022 2022 June 24, 2021 ( "2021 2021 2021 second 2022. On July 6, 2022, 2022 2022 During quarter ended September 30, 2022 |
Note 9 - Fair Value Measurement
Note 9 - Fair Value Measurements | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 9. The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. The requirement requires judgements to be made. Our Level 3 no 3 3 3 not A reconciliation of the beginning and ending balances for the warrant liabilities which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Warrant Liabilities Balance December 31, 2022 $ (534 ) Fair Value Adjustment - March 31, 2023 (629 ) Balance March 31, 2023 (1,163 ) Fair Value Adjustment - April 18, 2023 (1,522 ) Reclassification to Additional paid in capital 2,685 Balance June 30, 2023 $ — The Company uses the Lattice Model to value the Level 3 3 The following weighted-average input assumptions were used in determining the fair value of the note at inception, as of June 30, 2023, September 30, 2023 May 17, 2023, June 30, 2023, September 30, 2023 May 17, 2023, June 30, 2023, September 30, 2023 A reconciliation of the beginning and ending balances for the note payable which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Note Payable Credit Risk Change Accrued Interest Total Fair Value Balance March 31, 2023 $— $— $— $— Initial Transaction Fair Value - May 17 15,000 — — 15,000 Accrued Paid-in-Kind (PIK) Interest as of June 30, 2023 — — 185 185 Fair Value Adjustment - June 30, 2023 640 — — 640 Balance June 30, 2023 15,640 — 185 15,825 Accrued Paid-in-Kind (PIK) Interest added to Principal 185 — (185 ) — Accrued Paid-in-Kind (PIK) Interest as of September 30, 2023 — — 383 383 Fair Value Adjustment - September 30, 2023 (3,832 ) (1,208 ) — (5,040 ) Balance September 30, 2023 $ 11,993 $ (1,208 ) $ 383 $ 11,168 |
Note 10 - Other Income and Expe
Note 10 - Other Income and Expense | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Other Nonoperating Income and Expense [Text Block] | 10. Other (expense) income consists of loss from extinguishment of debt, interest expense, foreign exchange gain/(loss), fair value change from warrants, gain/(loss) on disposal of assets and other. Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 Gain/(Loss) from extinguishment of debt $ — $ — $ 2,611 $ — Change in fair value - note payable 3,832 — 3,192 — Interest expense (211 ) 44 (545 ) 31 Foreign exchange gain/(loss) 287 631 109 915 Fair value change - warrants — 2,784 (2,151 ) 2,784 Gain/(Loss) on disposal of assets (467 ) 11 (321 ) 11 Other 568 (426 ) 701 75 $ 4,009 $ 3,044 $ 3,596 $ 3,816 |
Note 11 - Forbearance Agreement
Note 11 - Forbearance Agreement and Convertible Note | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Long-Term Debt [Text Block] | 11. On May 17, 2023, The Forbearance Agreement provides that the supplier agrees to forbear from exercising rights and remedies available as a result of existing overdue amounts under existing agreements, so long as the Company pays to the supplier an aggregate of $11.8 million in deferred accounts payable, in monthly payments of $0.25 million, commencing in October 2023. The Company accounted for the restructuring as an extinguishment and recorded the new liabilities at fair value of $7.9 million for the deferred accounts payable and $15.0 million for the Note. The Company recorded a gain on extinguishment of $2.6 million as a result of the restructuring. The Note bears interest at a rate of 10.0% per annum, which shall be capitalized and added to the principal amount semi-annually on January 1 July 1, July 1, 2023, May 17, 2026. may The Company has elected the fair value option under ASC 825 10 25 825 10 15. June 30, 2023 September 30, 2023 nine September 30, 2023 $1.2 9, The Note is an unsecured obligation. The Note is unconditionally and irrevocably guaranteed by certain guarantors. If an Event of Default occurs under points ( 1 6 may 4 5 An Event of Default is defined in the Agreement as any of the following: 1. Company defaults in the payment of principal, accrued and unpaid interest or any other amounts owing under the Note 2. Any representation or warranty made by the Company proves to have been false 3. The Company defaults in the performance of, or fails to comply with, any other terms, provision, condition, covenant or agreement contained in the Note 4. Company files for bankruptcy 5. Court appoints a custodian, receiver, trustee or other officer for dissolution, winding-up, or liquation of the Company 6. One or more judgments for payment of money in excess of $3 million shall be rendered against the Company The deferred accounts payable does not October 2023 not first October 2023. |
Note 12 - Restructuring Charges
Note 12 - Restructuring Charges | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Restructuring and Related Activities Disclosure [Text Block] | 12. In June 2022, May 31, 2022. June 30, 2022. The Company’s restructuring efforts are intended to preserve cash and reduce operating expenses going forward. In addition to the workforce reductions, the Company’s restructuring efforts include the reduction of our internal research function, the decommissioning of certain equipment and pausing our manufacturing and process development efforts toward commercializing our MultiStem product candidate. The following table sets forth certain details associated with the restructuring charges incurred in the three nine September 30, 2023 2023. Balances Cash Balances January 1, 2023 Charges (payments) September 30, 2023 Employee severance and benefits $ 935 $ — $ (621 ) $ 314 Legal and professional fees 35 61 (65 ) 31 Other 15 — (15 ) — $ 985 $ 61 $ (701 ) $ 345 Balances Cash Balances June 30, 2023 Charges (payments) September 30, 2023 Employee severance and benefits $ 314 $ — $ — $ 314 Legal and professional fees 27 30 (26 ) 31 Other — — — — $ 341 $ 30 $ (26 ) $ 345 The current portion of our restructuring accrual is included in accrued compensation and related benefits and accounts payable and there is no long-term portion of our restructuring accrual. Restructuring charges are recorded general and administrative costs and expenses for the three September 30, 2023 |
Note 13 - Income Taxes
Note 13 - Income Taxes | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 13. We have United States (“U.S.”) federal net operating loss and research and development tax credit carryforwards, as well as state and city net operating loss carryforwards, which may not October 2012 382 1986, October 2012 may may not 382 October 2012 September 30, 2023 382 |
Note 14 - Subsequent Events
Note 14 - Subsequent Events | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 14. Animal Health Transaction On October 3, 2023, first Healios Update On October 10, 2023, “October January 8, 2016, October Under the Fifth Amendment to License Agreement, the Company agreed to grant Healios a non-exclusive worldwide license to develop and commercialize MultiStem with respect to treating acute respiratory distress syndrome (“ARDS”) in exchange for potential development and sales milestone payments and additional royalties totaling up to $150 million in the aggregate. The Assignment Agreement provides for ABT Holding’s assignment of certain MultiStem doses manufactured by using a 3D October 12, 2023, first November 9, 2023, second may Nasdaq Notices On October 14, 2022, “October 2022 not $35 5550 2 $35 30 October 10, 2023, October 12, 2023, October 13, 2023, On October 16, 2023, October 18, 2023. 25 The Company’s common stock is currently quoted on the Pink Open Market tier operated by OTC Markets Group, Inc. under the symbol “ATHX.” Warrant Inducement Offer, Warrant Restructure Transaction, and Related Agreements On October 11, 2023, August 17, 2022, September 22, 2022, November 10, 2022, August 21, 2023. On October 30, 2023, 1 $0.1395 2 3 60 30 March 1, 2024 may October 30, 2023, $0.01 October 30, 2028. Biomedical Advanced Research and Development (BARDA) As previously disclosed, the Company responded to a request for proposal by the Biomedical Advanced Research and Development Authority, an agency within the U.S. Department of Health and Human Services (“BARDA”), with a view to include MultiStem in a BARDA-sponsored phase 2 On October 13, 2023, not |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10 December 31, 2022 April 3, 2023. X. not not The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10 2. |
Stockholders' Equity, Policy [Policy Text Block] | Reverse Stock Split On August 26, 2022, 1 not third |
Note 4 - Net Loss Per Share (Ta
Note 4 - Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 Stock options 1,119,369 1,280,173 1,119,369 1,280,173 Restricted stock units 301,029 103,065 301,029 103,065 Convertible Note - refer to Note 11 11,538,461 — 11,538,461 — Warrants - refer to Note 8 45,714,090 3,920,000 45,714,090 4,320,000 Total 58,672,949 5,303,238 58,672,949 5,703,238 |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment, Net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | For the periods ended September 30, December 31, Property and equipment consists of (in thousands): 2023 2022 Laboratory equipment $ 8,352 $ 7,576 Office equipment and leasehold improvements 3,398 3,934 Equipment not yet in service 2,850 2,313 14,600 13,823 Accumulated depreciation and amortization (10,364 ) (9,609 ) $ 4,236 $ 4,214 |
Note 6 - Collaborative Arrang_2
Note 6 - Collaborative Arrangements and Revenue Recognition (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three months ended Three months ended September 30, 2023 September 30, 2022 Point in Point in Time Over Time Time Over Time Contract Revenue from Healios Product supply revenue $ — $ — $ — $ — Service revenue — — — 65 Total disaggregated revenues $ — $ — $ — $ 65 Nine months ended Nine months ended September 30, 2023 September 30, 2022 Point in Point in Time Over Time Time Over Time Contract Revenue from Healios Product supply revenue $ 49 $ — $ — $ — Service revenue — — — 5,294 Total disaggregated revenues $ 49 $ — $ — $ 5,294 |
Note 9 - Fair Value Measureme_2
Note 9 - Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Payable to Banks [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Note Payable Credit Risk Change Accrued Interest Total Fair Value Balance March 31, 2023 $— $— $— $— Initial Transaction Fair Value - May 17 15,000 — — 15,000 Accrued Paid-in-Kind (PIK) Interest as of June 30, 2023 — — 185 185 Fair Value Adjustment - June 30, 2023 640 — — 640 Balance June 30, 2023 15,640 — 185 15,825 Accrued Paid-in-Kind (PIK) Interest added to Principal 185 — (185 ) — Accrued Paid-in-Kind (PIK) Interest as of September 30, 2023 — — 383 383 Fair Value Adjustment - September 30, 2023 (3,832 ) (1,208 ) — (5,040 ) Balance September 30, 2023 $ 11,993 $ (1,208 ) $ 383 $ 11,168 |
Warrant [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Warrant Liabilities Balance December 31, 2022 $ (534 ) Fair Value Adjustment - March 31, 2023 (629 ) Balance March 31, 2023 (1,163 ) Fair Value Adjustment - April 18, 2023 (1,522 ) Reclassification to Additional paid in capital 2,685 Balance June 30, 2023 $ — |
Note 10 - Other Income and Ex_2
Note 10 - Other Income and Expense (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Schedule of Other Nonoperating Income (Expense) [Table Text Block] | Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 Gain/(Loss) from extinguishment of debt $ — $ — $ 2,611 $ — Change in fair value - note payable 3,832 — 3,192 — Interest expense (211 ) 44 (545 ) 31 Foreign exchange gain/(loss) 287 631 109 915 Fair value change - warrants — 2,784 (2,151 ) 2,784 Gain/(Loss) on disposal of assets (467 ) 11 (321 ) 11 Other 568 (426 ) 701 75 $ 4,009 $ 3,044 $ 3,596 $ 3,816 |
Note 12 - Restructuring Charg_2
Note 12 - Restructuring Charges (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Schedule of Restructuring Reserve by Type of Cost [Table Text Block] | Balances Cash Balances January 1, 2023 Charges (payments) September 30, 2023 Employee severance and benefits $ 935 $ — $ (621 ) $ 314 Legal and professional fees 35 61 (65 ) 31 Other 15 — (15 ) — $ 985 $ 61 $ (701 ) $ 345 Balances Cash Balances June 30, 2023 Charges (payments) September 30, 2023 Employee severance and benefits $ 314 $ — $ — $ 314 Legal and professional fees 27 30 (26 ) 31 Other — — — — $ 341 $ 30 $ (26 ) $ 345 |
Note 1 - Background and Basis_2
Note 1 - Background and Basis of Presentation (Details Textual) | 9 Months Ended | |
Aug. 26, 2022 | Sep. 30, 2023 | |
Number of Operating Segments | 1 | |
Reverse Stock Split [Member] | ||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Cash and Cash Equivalents, at Carrying Value | $ 1,020 | $ 9,038 |
Note 4 - Net Loss Per Share (De
Note 4 - Net Loss Per Share (Details Textual) - shares | Aug. 31, 2023 | Apr. 30, 2023 | Nov. 30, 2022 | Sep. 30, 2022 | Aug. 31, 2022 | Aug. 31, 2021 |
Healios Framework Agreement [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 28,600,000 | 3,685,000 | 9,109,090 | 2,000,000 | 1,920,000 | 400,000 |
Note 4 - Net Loss Per Share - A
Note 4 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Antidilutive securities (in shares) | 58,672,949 | 5,303,238 | 58,672,949 | 5,703,238 |
Share-Based Payment Arrangement, Option [Member] | ||||
Antidilutive securities (in shares) | 1,119,369 | 1,280,173 | 1,119,369 | 1,280,173 |
Restricted Stock Units (RSUs) [Member] | ||||
Antidilutive securities (in shares) | 301,029 | 103,065 | 301,029 | 103,065 |
Convertible Debt Securities [Member] | ||||
Antidilutive securities (in shares) | 11,538,461 | 0 | 11,538,461 | 0 |
Warrant [Member] | ||||
Antidilutive securities (in shares) | 45,714,090 | 3,920,000 | 45,714,090 | 4,320,000 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Impairment, Long-Lived Asset, Held-for-Use | $ 7,900 | $ 7,200 | ||
Property, Plant and Equipment, Disposals | 1,000 | 0 | ||
Restructuring and Related Cost, Accelerated Depreciation | $ 900 | 400 | 400 | |
Proceeds from Sale of Property, Plant, and Equipment | 300 | |||
Gain (Loss) on Disposition of Property Plant Equipment | $ (467) | $ 11 | $ (321) | $ 11 |
Note 5 - Property and Equipme_4
Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Property and equipment, gross | $ 14,600 | $ 13,823 |
Accumulated depreciation and amortization | (10,364) | (9,609) |
Property, Plant and Equipment, Net | 4,236 | 4,214 |
Equipment [Member] | ||
Property and equipment, gross | 8,352 | 7,576 |
Office Equipment and Leasehold Improvements [Member] | ||
Property and equipment, gross | 3,398 | 3,934 |
Equipment Not Yet in Service [Member] | ||
Property and equipment, gross | $ 2,850 | $ 2,313 |
Note 6 - Collaborative Arrang_3
Note 6 - Collaborative Arrangements and Revenue Recognition (Details Textual) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
Sep. 30, 2022 USD ($) shares | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) shares | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) shares | Aug. 31, 2023 USD ($) shares | Apr. 30, 2023 shares | Nov. 30, 2022 shares | Aug. 31, 2022 shares | Aug. 31, 2021 USD ($) shares | Dec. 31, 2017 | |
Healios Framework Agreement [Member] | |||||||||||
Accounts Receivable, after Allowance for Credit Loss, Current | $ 700,000 | $ 700,000 | |||||||||
Revenue From Contract With Customer, Potential Revenue From Milestones | $ 3,000,000 | ||||||||||
Revenue From Contract With Customer, Milestones Obligation to Pay | $ 1,100,000 | ||||||||||
Revenue from Contract with Customer, Including Assessed Tax | $ 1,900,000 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | shares | 2 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 2,000,000 | 2,000,000 | 2,000,000 | 28,600,000 | 3,685,000 | 9,109,090 | 1,920,000 | 400,000 | |||
Number of Performance Obligation for Services Necessary for Regulatory Approvals | 1 | ||||||||||
Contract with Customer, Liability, Revenue Recognized | 0 | $ 0.1 | $ 0 | $ 2,800,000 | |||||||
Contract with Customer, Performance Obligation Satisfied in Previous Period | $ 0 | $ 0 | |||||||||
Number of Future Milestones Achieved | 2 | ||||||||||
Healios Framework Agreement [Member] | Minimum [Member] | |||||||||||
Contract with Customer, Asset, Threshold Period Past Due (Day) | 30 days | 30 days | |||||||||
Healios Framework Agreement [Member] | Maximum [Member] | |||||||||||
Contract with Customer, Asset, Threshold Period Past Due (Day) | 45 days | 45 days | |||||||||
Healios Memorandum of Understanding [Member] | |||||||||||
Contract with Customer, Liability | $ 150,000 |
Note 6 - Collaborative Arrang_4
Note 6 - Collaborative Arrangements and Revenue Recognition - Disaggregation of Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Contract revenue from Healios | $ 0 | $ 65 | $ 49 | $ 5,294 |
Transferred at Point in Time [Member] | ||||
Contract revenue from Healios | 0 | 0 | 49 | 0 |
Transferred over Time [Member] | ||||
Contract revenue from Healios | 0 | 65 | 0 | 5,294 |
Product [Member] | Transferred at Point in Time [Member] | ||||
Contract revenue from Healios | 0 | 0 | 49 | 0 |
Product [Member] | Transferred over Time [Member] | ||||
Contract revenue from Healios | 0 | 0 | 0 | 0 |
Service [Member] | Transferred at Point in Time [Member] | ||||
Contract revenue from Healios | 0 | 0 | 0 | 0 |
Service [Member] | Transferred over Time [Member] | ||||
Contract revenue from Healios | $ 0 | $ 65 | $ 0 | $ 5,294 |
Note 7 - Stock-based Compensa_2
Note 7 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 27, 2022 | |
Share-Based Payment Arrangement, Expense | $ 0.7 | $ 2 | ||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 3.2 | $ 3.2 | ||
Inducement Stock Options [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 429,500 | 429,500 | ||
The 2019 Equity and Incentive Compensation Plan [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 3,700,000 | 3,700,000 | ||
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) | 1,185,543 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 2,095,332 | 2,095,332 | 2,000,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number (in shares) | 990,898 | 990,898 | ||
Expired Incentive Plan [Member] | ||||
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) | 11,289 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number (in shares) | 19,084 | 19,084 |
Note 8 - Stockholders' Equity_2
Note 8 - Stockholders' Equity and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||||||
Oct. 11, 2023 | Aug. 21, 2023 | Aug. 17, 2023 | Apr. 18, 2023 | Nov. 09, 2022 | Sep. 22, 2022 | Aug. 15, 2022 | Aug. 31, 2021 | Sep. 30, 2023 | Jun. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Oct. 30, 2023 | Apr. 17, 2023 | Dec. 31, 2022 | May 12, 2022 | Jun. 30, 2021 | |
Common Stock, Shares Authorized (in shares) | 600,000,000 | 600,000,000 | 600,000,000 | 600,000,000 | 600,000,000 | |||||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||||
Preferred Stock, Shares Issued (in shares) | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Fair Value Adjustment of Warrants | $ 0 | $ (2,784) | $ 2,151 | $ (2,784) | ||||||||||||||
Adjustments to Additional Paid in Capital, Warrant Issued | $ 2,685 | |||||||||||||||||
Issuance Costs Allocated to Warrant Liabilities | 500 | 0 | 560 | |||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 400 | |||||||||||||||||
Proceeds from Warrant Exercises | 1 | 2 | ||||||||||||||||
August 2022 Pre-Funded Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 720,000 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0025 | |||||||||||||||||
August 2022 Common Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,920,000 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 6 months | 6 months | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 7 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.385 | |||||||||||||||||
September Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,000,000 | 2,000,000 | 1,760,000 | |||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 6 months | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 7 years | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.385 | |||||||||||||||||
August Warrants and September Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.32 | $ 0.96 | ||||||||||||||||
Fair Value Adjustment of Warrants | $ 0 | $ 2,200 | 2,800 | |||||||||||||||
Proceeds from Issuance of Warrants | $ 400 | |||||||||||||||||
August Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,920,000 | 1,920,000 | ||||||||||||||||
November 2022 Pre-Funded Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,077,270 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0001 | |||||||||||||||||
November 2022 Common Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 10,009,090 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 2 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.1 | |||||||||||||||||
April 2023 Pre-Funded Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,370,000 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 6 months | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0001 | |||||||||||||||||
April 2023 Common Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,685,000 | |||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 6 months | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 7 years | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.96 | |||||||||||||||||
August 2023 Pre-funded Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,725,000 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0001 | |||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 6,725,000 | 6,725,000 | ||||||||||||||||
August 2023 Series A Common Stock Purchase Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 10,937,500 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.32 | |||||||||||||||||
August 2023 Series B Common Stock Purchase Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 10,937,500 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 6 months | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.32 | |||||||||||||||||
Inducement Warrant Shares [Member] | Subsequent Event [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 56,249,080 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.1395 | $ 0.01 | ||||||||||||||||
Warrants or Rights, Percent of Stock Purchasable | 200% | |||||||||||||||||
Proceeds from Warrant Exercises | $ 3,900 | |||||||||||||||||
Existing Warrants [Member] | Subsequent Event [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 28,124,540 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.1395 | $ 0.01 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 3,900 | |||||||||||||||||
The New Warrants [Member] | Subsequent Event [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 20,000,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | |||||||||||||||||
The 2021 Warrants [Member] | Healios [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 400,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Cap Triggering Percentage | 19.90% | |||||||||||||||||
The 2021 Warrants, Type One [Member] | Healios [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 120,000 | |||||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 60 days | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 45 | |||||||||||||||||
The 2021 Warrants, Type Two [Member] | Healios [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 280,000 | |||||||||||||||||
Warrants and Rights, Exercisable Period (Month) | 60 days | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 60 | |||||||||||||||||
August 2022 Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,200,000 | |||||||||||||||||
Number of Shares Per Unit Issued (in shares) | 1 | |||||||||||||||||
Equity Offering, Unit Purchase Price (in dollars per share) | $ 6.25 | |||||||||||||||||
Equity Offering, Deduction Per Unit for Prefunded Warrant (in dollars per share) | $ 0.0025 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 11,000 | |||||||||||||||||
Fair Value Adjustment of Warrants | (800) | |||||||||||||||||
Adjustments to Additional Paid in Capital, Warrant Issued | $ 3,800 | |||||||||||||||||
Equity Offering, Participation Right Percentage | 30% | |||||||||||||||||
August 2022 Securities Purchase Agreement [Member] | Placement Agent Fee [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 800 | |||||||||||||||||
August 2022 Securities Purchase Agreement [Member] | Reimbursement of Expense [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 100 | |||||||||||||||||
November 2022 Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,927,275 | |||||||||||||||||
Number of Shares Per Unit Issued (in shares) | 1 | |||||||||||||||||
Equity Offering, Unit Purchase Price (in dollars per share) | $ 1.1 | |||||||||||||||||
Equity Offering, Deduction Per Unit for Prefunded Warrant (in dollars per share) | $ 0.0001 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 5,000 | |||||||||||||||||
November 2022 Securities Purchase Agreement [Member] | Placement Agent Fee [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | 400 | |||||||||||||||||
November 2022 Securities Purchase Agreement [Member] | Reimbursement of Expense [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 100 | |||||||||||||||||
April 2023 Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,315,000 | |||||||||||||||||
Number of Shares Per Unit Issued (in shares) | 1 | |||||||||||||||||
Equity Offering, Unit Purchase Price (in dollars per share) | $ 1 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 3,400 | |||||||||||||||||
April 2023 Securities Purchase Agreement [Member] | Placement Agent Fee [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | 200 | |||||||||||||||||
April 2023 Securities Purchase Agreement [Member] | Reimbursement of Expense [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 100 | |||||||||||||||||
August 2023 Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,212,500 | |||||||||||||||||
Equity Offering, Unit Purchase Price (in dollars per share) | $ 0.32 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 3,000 | |||||||||||||||||
August 2023 Securities Purchase Agreement [Member] | A.G.P. [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 200 | |||||||||||||||||
August 2023 Securities Purchase Agreement [Member] | Reimbursement of Expenses [Member] | A.G.P. [Member] | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 200 | |||||||||||||||||
The 2022 Equity Facility [Member] | ||||||||||||||||||
Equity Offering, Maximum Shares Committed | $ 100,000 | |||||||||||||||||
The 2021 Equity Facility [Member] | ||||||||||||||||||
Equity Offering, Maximum Shares Committed | $ 100,000 | |||||||||||||||||
The 2021 Equity Facility [Member] | Aspire Capital [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 |
Note 9 - Fair Value Measureme_3
Note 9 - Fair Value Measurements (Details Textual) - Notes Payable to Banks [Member] | Sep. 30, 2023 | Jun. 30, 2023 | May 17, 2023 |
Measurement Input, Price Volatility [Member] | |||
Long-Term Debt, Measurement Input | 0.779 | 0.506 | 0.495 |
Measurement Input, Bond Yield Rate [Member] | |||
Long-Term Debt, Measurement Input | 0.307 | 0.196 | 0.189 |
Note 9 - Fair Value Measureme_4
Note 9 - Fair Value Measurements - Reconciliation of Warrant Liabilities (Details) - Warrant [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2023 | Mar. 31, 2023 | |
Balance | $ (1,163) | $ (534) |
Fair Value Adjustment | (1,522) | (629) |
Reclassification to Additional paid in capital | 2,685 | |
Balance | $ 0 | $ (1,163) |
Note 9 - Fair Value Measureme_5
Note 9 - Fair Value Measurements - Reconciliation of Note Payable (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2023 | Jun. 30, 2023 | |
Notes Payable to Banks [Member] | ||
Balance | $ 15,640 | |
Initial Transaction Fair Value - May 17 | 15,000 | |
Accrued Paid-in-Kind (PIK) Interest | 0 | 0 |
Fair Value Adjustment | 3,832 | 640 |
Accrued Paid-in-Kind (PIK) Interest added to Principal | 185 | |
Fair Value Adjustment | (3,832) | (640) |
Balance | 11,993 | 15,640 |
Credit Risk Change [Member] | ||
Balance | 0 | |
Initial Transaction Fair Value - May 17 | 0 | |
Accrued Paid-in-Kind (PIK) Interest | 0 | 0 |
Fair Value Adjustment | 1,208 | 0 |
Accrued Paid-in-Kind (PIK) Interest added to Principal | 0 | |
Fair Value Adjustment | (1,208) | 0 |
Balance | (1,208) | 0 |
Accrued Interest [Member] | ||
Balance | 185 | |
Initial Transaction Fair Value - May 17 | 0 | |
Accrued Paid-in-Kind (PIK) Interest | 383 | 185 |
Fair Value Adjustment | 0 | 0 |
Accrued Paid-in-Kind (PIK) Interest added to Principal | (185) | |
Fair Value Adjustment | 0 | 0 |
Balance | 383 | 185 |
Notes Payable, Including Accrued Interest [Member] | ||
Balance | 15,825 | |
Initial Transaction Fair Value - May 17 | 15,000 | |
Accrued Paid-in-Kind (PIK) Interest | 383 | 185 |
Fair Value Adjustment | 5,040 | 640 |
Accrued Paid-in-Kind (PIK) Interest added to Principal | 0 | |
Fair Value Adjustment | (5,040) | (640) |
Balance | $ 11,168 | $ 15,825 |
Note 10 - Other Income and Ex_3
Note 10 - Other Income and Expense - Other (Expense) Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | ||
Gain/(Loss) from extinguishment of debt | $ 0 | $ 0 | $ 2,611 | $ 0 | |
Change in fair value - note payable | (3,832) | 0 | (3,192) | 0 | |
Interest expense | (211) | 44 | (545) | 31 | |
Foreign exchange gain/(loss) | 287 | 631 | 109 | 915 | |
Fair value change - warrants | 0 | 2,784 | (2,151) | 2,784 | |
Gain/(Loss) on disposal of assets | (467) | 11 | (321) | 11 | |
Other | 568 | (426) | 701 | 75 | |
Nonoperating Income (Expense) | [1] | $ 4,009 | $ 3,044 | $ 3,596 | $ 3,816 |
[1]See Footnote 10 for components of other income, net |
Note 11 - Forbearance Agreeme_2
Note 11 - Forbearance Agreement and Convertible Note (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||
May 17, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Jun. 30, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | |
Forbearance Agreement, Deferred Accounts Payable | $ 11,800,000 | |||||
Forbearance Agreement, Deferred Accounts Payable, Monthly Payments | 250,000 | |||||
Deferred Accounts Payable, Fair Value | $ 7,900,000 | |||||
Gain (Loss) on Extinguishment of Debt | $ 0 | $ 0 | $ 2,611,000 | $ 0 | ||
Paid-in-Kind Interest | 568,000 | 0 | ||||
Change in Fair Value of Note Payables | (3,832,000) | 0 | (3,192,000) | 0 | ||
Forbearance Agreement, Deferred Accounts Payable, Payment Term (Month) | 48 months | |||||
Forbearance Agreement, Deferred Accounts Payable, Cash Payment Not Paid When Due Subject to Interest Rate | 10% | |||||
Forbearance Agreement, Deferred Accounts Payable, Cash Payment Due Benchmark Period (Day) | 60 days | |||||
OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), after Adjustments and Tax, Parent | 1,208,000 | $ 0 | 1,208,000 | $ 0 | ||
Convertible Debt [Member] | Supplier [Member] | ||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||
Gain (Loss) on Extinguishment of Debt | $ 2,600,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | |||||
Debt Instrument, Event of Default, Payment | $ 3,000,000 | |||||
Debt Instrument, Event of Default, Interest Rate | 14% | |||||
Debt Instrument, Convertible, Beneficial Ownership Limitation | 19.99% | |||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.3 | |||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 11,538,461 | |||||
Debt Instrument, Convertible, Conversion Period After Date of Issuance (Month) | 18 months | |||||
Debt Issuance Costs, Net | $ 16,679 | |||||
Notes Payable, Fair Value Disclosure | $ 10,800,000 | $ 15,800,000 | 10,800,000 | |||
Paid-in-Kind Interest | 200,000 | 400,000 | ||||
Change in Fair Value of Note Payables | 600,000 | |||||
Debt Instrument, Event of Default, Percentage of Principal for Acceleration of Maturity | 100% | |||||
Debt Instrument, Event of Default, Percentage of Principal Automatically and Immediately Due | 100% | |||||
Debt Instrument, Event of Default, Judgement Payment Rendered Against Company | $ 3,000,000 | |||||
OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), after Adjustments and Tax, Parent | 1,200,000 | |||||
Convertible Debt [Member] | Supplier [Member] | Other Nonoperating Income (Expense) [Member] | ||||||
Fair Value, Option, Changes in Fair Value, Gain (Loss) | $ 800,000 | $ 3,800,000 |
Note 12 - Restructuring Charg_3
Note 12 - Restructuring Charges (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | |
Jun. 30, 2022 | Sep. 30, 2023 | |
Restructuring and Related Cost, Reduction in Workforce, Percentage | 70% | |
Restructuring Reserve, Noncurrent | $ 0 |
Note 12 - Restructuring Charg_4
Note 12 - Restructuring Charges - Restructuring Charges (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2023 | Sep. 30, 2023 | |
Balances | $ 341 | $ 985 |
Charges | 30 | 61 |
Cash (Payments) | (26) | (701) |
Balances | 345 | 345 |
Employee Severance [Member] | ||
Balances | 314 | 935 |
Charges | 0 | 0 |
Cash (Payments) | 0 | (621) |
Balances | 314 | 314 |
Legal and Professional Fees [Member] | ||
Balances | 27 | 35 |
Charges | 30 | 61 |
Cash (Payments) | (26) | (65) |
Balances | 31 | 31 |
Other Restructuring [Member] | ||
Balances | 0 | 15 |
Charges | 0 | 0 |
Cash (Payments) | 0 | (15) |
Balances | $ 0 | $ 0 |
Note 14 - Subsequent Events (De
Note 14 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions | Nov. 09, 2023 | Oct. 12, 2023 | Oct. 11, 2023 | Oct. 30, 2023 | Oct. 10, 2023 | Oct. 03, 2023 |
Inducement Warrant Shares [Member] | ||||||
Warrants or Rights, Percent of Stock Purchasable | 200% | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 56,249,080 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.1395 | $ 0.01 | ||||
Inducement Warrant Shares [Member] | Maximum [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 56,249,080 | |||||
Existing Warrants [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 28,124,540 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.1395 | $ 0.01 | ||||
Proceeds from Issuance or Sale of Equity | $ 3.9 | |||||
Existing Warrants [Member] | Maximum [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 28,124,540 | |||||
The New Warrants [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 20,000,000 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | |||||
Licensing Agreement With Ardent [Member] | ||||||
License Agreement, Initial Fee | $ 0.1 | |||||
Fifth Amendment to License Agreement [Member] | ||||||
License Agreement, Potential Development and Sales Milestone Payments and Royalties | $ 150 | |||||
Revenue from Contract with Customer, Including Assessed Tax | $ 1.5 | $ 1.5 | ||||
License Agreement, Expected Payments | $ 1.5 |